Latest News for ICCC
ICCC's Q2 sales rise 11.5% y/y, but margins contract. A $2-million legal settlement boosts profit as the company plans a capacity expansion.
ImmuCell Corporation (NASDAQ: ICCC - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $8.64 and traded as high as $10.49. ImmuCell shares last traded at $10.06, with a volume of 11,130 shares traded. Analysts Set New Price Targets A number
ImmuCell Corporation (ICCC) Q2 2026 Earnings Call Transcript
ImmuCell NASDAQ: ICCC reported higher second-quarter sales and earnings as domestic demand for its calf scours prevention products increased, while the company outlined plans to invest about $8 million to more than triple manufacturing capacity by the end of 2027.
PORTLAND, Maine, Aug. 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced its unaudited financial results for the quarter ended June 30, 2026.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ICCC.
U.S. House Trading
No House trades found for ICCC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.